Selected Toxicities of Targeted Therapies: Presentation and Management

被引：7

作者：

Kollmannsberger, Christian ^{[1
]}

Mitchell, Teresa ^{[1
]}

机构：

[1] British Columbia Canc Agcy, Vancouver Canc Ctr, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada

来源：

SEMINARS IN ONCOLOGY | 2013年 / 40卷 / 04期

关键词：

RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; INTERFERON-ALPHA; FACTOR RECEPTOR; SUNITINIB; EFFICACY; HYPERTENSION; EVEROLIMUS; TEMSIROLIMUS; BEVACIZUMAB;

D O I：

10.1053/j.seminoncol.2013.05.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The introduction of targeted therapy has changed the landscape of metastatic renal cell carcinoma (mRCC) but has also brought challenges. One such challenge of treating this chronic disease is long-term therapy, which produces ongoing toxicity. Knowledge of the spectrum of toxicity from targeted therapy and appropriate and timely intervention is required to maintain adequate dosing required for optimal outcome. This article addresses some of the major toxicities of newer agents in RCC and discusses management strategies. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：499 / 510

页数：12

共 50 条

[31] Toxicities of Targeted Therapy and Their Management in Kidney Cancer
Di Lorenzo, Giuseppe
Porta, Camillo
Bellmunt, Joaquim
Sternberg, Cora
Kirkali, Ziya
Staehler, Michael
Joniau, Steven
Montorsi, Francesco
Buonerba, Carlo
EUROPEAN UROLOGY, 2011, 59 (04) : 526 - 540
[32] Targeted therapies in the medical management of craniopharyngioma
Pedro Iglesias
Pituitary, 2022, 25 : 383 - 392
[33] Targeted therapies in the medical management of craniopharyngioma
Iglesias, Pedro
PITUITARY, 2022, 25 (03) : 383 - 392
[34] The toxicities of modern targeted therapies-learning from the price of progress
Giles, Francis J.
TARGETED ONCOLOGY, 2009, 4 (02) : 65 - 66
[35] A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers
Urban, Christopher
Anadkat, Milan J.
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (03) : 319 - 327
[36] Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC
Waliany, Sarah
Zhu, Han
Wakelee, Heather
Padda, Sukhmani K.
Das, Millie
Ramchandran, Kavitha
Myall, Nathaniel J.
Chen, Thomas
Witteles, Ronald M.
Neal, Joel W.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2029 - 2039
[37] The flaws in assessing and reporting the toxicities of oral targeted therapies Everolimus as an example
Fojo, Tito
SEMINARS IN ONCOLOGY, 2023, 50 (1-2) : 1 - 6
[38] Non-rash skin toxicities associated with novel targeted therapies
Lacouture, Mario E.
Boerner, Scott A.
LoRusso, Patricia M.
CLINICAL LUNG CANCER, 2006, 8 : S36 - S42
[39] Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success
Cazzaniga, Marina Elena
Danesi, Romano
Girmenia, Corrado
Invernizzi, Pietro
Elvevi, Alessandra
Uguccioni, Massimo
Gila, Monica Perez
Amaducci, Laura
Atzori, Francesco
Blasi, Livio
Butti, Chiara
Collova, Elena
De Conciliis, Enrico
Fabi, Alessandra
Febbraro, Antonio
Garrone, Ornella
Gianni, Lorenzo
Giotta, Francesco
La Verde, Nicla
Michelotti, Andrea
Palumbo, Raffaella
Paris, Ida
Pistelli, Mirco
Pizzuti, Laura
Rubino, Daniela
Valerio, Maria Rosaria
Zustovich, Fable
BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (03) : 483 - 494
[40] Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success
Marina Elena Cazzaniga
Romano Danesi
Corrado Girmenia
Pietro Invernizzi
Alessandra Elvevi
Massimo Uguccioni
Breast Cancer Research and Treatment, 2019, 176 : 483 - 494

← 1 2 3 4 5 →